SGLT2 Inhibitor / Dc Cardioversion / SGLT2 inhibitors (Dapagliflozin and Empagliflozin) · Phase 4 Trial

Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

ClinicalTrials.gov · August 20, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a registered but actively recruiting Phase 4 open-label RCT examining whether SGLT2 inhibitors reduce atrial tachyarrhythmia recurrence at 1 month after electrical cardioversion in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. No results are yet available in this registry record.

What was studied

Phase 4, Interventional, Randomized, Parallel, Open label, Treatment purpose. Atrial Fibrillation, SGLT2 Inhibitor, DC Cardioversion; age from 19 Years. Intervention: SGLT2 inihibitor. Compared with: Control — No Intervention. n = 200. 1 site: South Korea.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a registered clinical trial currently recruiting with no results posted; it represents a planned Phase 4 study addressing an understudied question about SGLT2 inhibitors and rhythm maintenance post-cardioversion.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Recurrence of atrial tachyarrhythmia (assessed at 1 month after randomization (±1 week))

DesignPhase 4, Interventional, Randomized, Parallel, Open label, Treatment purpose

PopulationAtrial Fibrillation, SGLT2 Inhibitor, DC Cardioversion; age from 19 Years

Sample size200

InterventionSGLT2 inihibitor

ComparatorControl — No Intervention

Setting1 site: South Korea

Reported figures

Quoted from the source exactly as published.

Planned enrollment200

Randomization ratio1:1

Primary outcome measureRecurrence of atrial tachyarrhythmia, 1 month after randomization (±1 week)

Study phasePhase 4

Caveats

No results are posted in this registry record; the study is currently recruiting.
Open-label design without blinding may introduce bias in outcome assessment or participant behaviour.
Single-center study limits generalizability.
Primary outcome timepoint is only 1 month; longer-term rhythm maintenance is not addressed in this registered protocol.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Prospective single-center open-label RCT; lack of blinding limits rigor.

Directness

strong

Primary outcome directly addresses clinical question: recurrence of atrial tachyarrhythmia post-cardioversion.

Consistency

insufficient

No results reported; consistency cannot be assessed from registry record alone.

Risk of bias

limited

Open-label design introduces risk of bias; no blinding of participants or assessors described.

Sample adequacy

moderate

Planned enrollment 200 participants, 1:1 randomization; adequacy depends on effect size assumption.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07776054). This is a study registration, not published results. Lead sponsor: Samsung Medical Center. Recruitment status: RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 200 participants (ESTIMATED). Conditions: Atrial Fibrillation, SGLT2 Inhibitor, DC Cardioversion. Interventions: DRUG: SGLT2 inhibitors (Dapagliflozin and Empagliflozin). Primary outcome measures: Recurrence of atrial tachyarrhythmia , 1 month after randomization (±1 week). Brief summary: SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Samsung Medical CenterSGLT2 InhibitorDc CardioversionSGLT2 inhibitors (Dapagliflozin and Empagliflozin)Atrial FibrillationNCT07776054